Apellis nets $382M through FOPO
Executive Summary
Apellis Pharmaceuticals Inc. (complement system inhibitors) netted $382M in a public offering of 10.9M shares (including full exercise of the overallotment) at $37. The company will use the proceeds to fund continued development and potential commercialization (including build-out of a commercial infrastructure and sales force) of lead candidate pegcetacoplan (APL2), a C3 inhibitor, in Phase III for multiple indications. Concurrent with the financing, Apellis announced topline results from a Phase III study in paroxysmal nocturnal hemoglobinuria, for which the candidate has a 66% likelihood of approval (7% above average).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice